1612 GMT - Philips's cautious outlook for this year doesn't surprise after the company posted only slight order intake growth in 2024, ING analysts say in a note. The Dutch medical-device company's order intake grew 2% in the fourth quarter, bringing the annual growth rate to 1%, they say. With that in mind, it's unsurprising that the guidance for 1%-3% organic growth, including continued decline in China in 2025, was also a little weaker than expected, the analysts say. Divisionally, Philips posted a large adjusted Ebita shortfall in its core Diagnosis & Treatment division, offset by better-than-expected results in Connected Care, as the unit is recovering from its Respironics sleep apnea machines recall. Shares are down 12% at 23.81 euros.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 19, 2025 11:12 ET (16:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.